Received Oct 16, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (MODERNA MNEXSPIKE)) | MODERNA | UNK | — | IM |
| FLUX | INFLUENZA (SEASONAL) (NO BRAND NAME) | UNKNOWN MANUFACTURER | UNK | — | — |
subconjunctival hemorrhage; This spontaneous case was reported by a consumer and describes the occurrence of CONJUNCTIVAL HAEMORRHAGE (subconjunctival hemorrhage) in a female patient of an unknown age who received mRNA-1273.251 (Spikevax LP.8.1 PFS) for COVID-19 prophylaxis. Co-suspect product included non-company product Influenza vaccine (Flu) for an unknown indication. No Medical History information was reported. On 06-Oct-2025, the patient received dose of mRNA-1273.251 (Spikevax LP.8.1 PFS) (Intramuscular use) 1 dosage form and dose of Influenza vaccine (Flu) (unknown route) 1 dosage form. On 09-Oct-2025, the patient experienced CONJUNCTIVAL HAEMORRHAGE (subconjunctival hemorrhage). At the time of the report, CONJUNCTIVAL HAEMORRHAGE (subconjunctival hemorrhage) outcome was unknown. No concomitant medication was reported. After receiving the Moderna Covid vaccine and the flu vaccine on the afternoon of 06-Oct-2025, the patient suffered a subconjunctival hemorrhage overnight on 09-Oct to 10-Oct-2025. On 10-Oct-2025, the patient awoke with an eye that was half-filled with blood. It was unknown if the patient experienced any additional symptoms/events. No treatment medication was reported.